Chaperone-Mediated Autophagy Markers LAMP2A and HSC70 Are Independent Adverse Prognostic Markers in Primary Resected Squamous Cell Carcinomas of the Lung by Losmanová, Tereza et al.
Research Article
Chaperone-Mediated Autophagy Markers LAMP2A and
HSC70 Are Independent Adverse Prognostic Markers in Primary
Resected Squamous Cell Carcinomas of the Lung
Tereza Losmanová,1 Félice A. Janser,1 Magali Humbert,1 Igor Tokarchuk,1,2
Anna M. Schläfli,1 Christina Neppl,1 Ralph A. Schmid,3,4 Mario P. Tschan,1,2
Rupert Langer,1,5 and Sabina Berezowska 1,6
1Institute of Pathology, University of Bern, Bern 3008, Switzerland
2Graduate School for Cellular and Biomedical Sciences, Bern 3012, Switzerland
3Division of General Thoracic Surgery, Inselspital University Hospital Bern, Bern 3010, Switzerland
4Department of Biomedical Research (DBMR), University of Bern, Bern 3008, Switzerland
5Institute of Pathology and Molecular Pathology, Kepler University Hospital, Johannes Kepler University Linz, 4021 Linz,
4040 Linz, Austria
6Institut de Pathologie, Centre Hospitalier Universitaire Vaudois et Université de Lausanne, Lausanne 1011, Switzerland
Correspondence should be addressed to Sabina Berezowska; sabina.berezowska@chuv.ch
Received 20 March 2020; Revised 11 August 2020; Accepted 1 September 2020; Published 22 September 2020
Academic Editor: Eva erovnik
Copyright © 2020 Tereza Losmanová et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
LAMP2A and HSC70 are crucial players in chaperone-mediated autophagy (CMA), a targeted, lysosome-dependent protein
degradation pathway. Elevated LAMP2A levels, indicative of increased CMA activity, are observed in several malignancies, and
CMA downregulation may be exploited therapeutically. We evaluated the impact of LAMP2A and HSC70 in pulmonary squamous
cell carcinomas (pSQCC). Antibodies were validated by knockdown and overexpression experiments using three different cell lines.
Expression levels in tissue were analyzed by immunohistochemistry in a cohort of 336 consecutive pSQCC using tissue
microarrays. There was no significant correlation between the two markers among each other and no association with pathological
parameters (TNM categories, grading). However, both high LAMP2A and HSC70 expression were associated with worse
outcome, including overall survival (OS; p = 0:012 and p = 0:001) and disease free survival (DFS; p = 0:049 and p = 0:036). In
multivariate analysis, both markers and a combination of them were independent adverse prognostic factors for OS
(LAMP2Ahigh: HR = 2:059; p < 0:001; HSC70high: HR = 1:987; p < 0:001; LAMP2Ahigh/HSC70high: HR = 1:529; p < 0:001) and
DFS (LAMP2Ahigh: HR = 1:709; p = 0:004; HSC70high: HR = 1:484; p = 0:027; LAMP2Ahigh/HSC70high: HR = 1:342, p < 0:001).
The negative prognostic impact of high LAMP2A and HSC70 and their variable expression in pSQCC may justify the use of these
proteins as potential biomarkers for future CMA-inhibiting therapies.
1. Introduction
Autophagy describes different lysosomal degradation path-
ways targeting damaged cytosolic proteins and organelles.
Deregulation of autophagy pathways is involved in many
physiological and pathophysiological mechanisms such as
cell aging, neurodegenerative disorders, lysosomal storage
diseases, and cancer [1]. However, the role of autophagy in
tumorigenesis and its prognostic impact is complex and
not fully understood. The term autophagy encompasses
three main pathways (macroautophagy, microautophagy,
and chaperone-mediated autophagy (CMA)) that differ in
how the targeted cytosolic content reaches the lysosome
for degradation [2]. In contrast to the highly conserved pro-
cess of macroautophagy, CMA is only observed in mamma-
lian cells. It is involved in the quality control of proteins by
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selectively degrading altered or damaged proteins. The
process is induced upon different stresses as for instance
hypoxia, and it is maximally activated upon prolonged cell
starvation [3, 4]. Briefly, CMA specific client proteins bear
a specific pentapeptide stretch, the KFERQ-like motif (Lys-
Phe-Glu-Arg-Gln) [5], which is recognized in the cytosol
by the heat shock cognate protein of 70 kDa (HSC70, also
known as HSPA8) within a cytosolic chaperone complex.
Then, the client protein is shuttled to the lysosome where
it is unfolded and translocated into the lysosome through a
multimeric complex of lysosome-associated membrane
protein 2A (LAMP2A) (Figure 1(a)) [6]. The binding of
the CMA target protein to LAMP2A monomer initiates a
multimerization process involving several LAMP2A pro-
teins. They form a translocation complex through which
the unfolded target protein is translocated for degradation
into the lysosomal lumen (Figure 1(a)) [7, 8]. Since the
expression and degradation of LAMP2A is tightly regulated,
this protein is considered the rate-limiting factor of the
CMA process.
HSC70 is a heat shock protein (HSPs). HSPs are a large
group of chaperones, which are induced upon different
stresses. A subclass is formed by the HSP70 family, which
includes at least 13 proteins including HSC70. This chaper-
one is present at the cellular membrane, extracellular exo-
somes, the nucleus, and the cytosol [9]. Its main function is
protein quality control, where it acts as a folding catalyst or
targets misfolded proteins for degradation [10, 11].
LAMP2A on the other hand is an alternative splice
variant of the protein encoded by LAMP2. LAMP2 is a
transmembrane glycoprotein in the lysosomal membrane
with three splice variants (LAMP2A, B, and C). The three
isoforms share some functions such as antigen presentation,
cholesterol trafficking, lysosome biogenesis, and phagocyto-
sis while some are specific to each isoform [12]. For instance,
LAMP2A is the unique LAMP2 essential for CMA.
As observed in several human cancer cell lines and in
primary tumor samples, CMA seems activated in different
cancer types, evidenced by markedly increased LAMP2A
levels [13, 14]. In vitro, inhibition of CMA leads to decreased
tumor cell survival, and in mouse cancer xenograft models,
CMA inhibition results in reduced metastases and tumor
shrinkage [13, 15]. However, this rather tumor supportive
effect of CMA is not fully understood, and it is important
to emphasize that under physiological conditions, CMA is
rather tumor suppressive [16]. Data on the expression of
CMA-related proteins in human cancers and their potential
impact on tumor aggressiveness or response to anticancer
treatment are still scarce.
Non-small cell lung cancer (NSCLC) is the leading cause
of cancer death in all European countries and worldwide
[17]. Among NSCLC, pulmonary squamous cell carcinoma
(pSQCC) is the second most common histological subtype.
It is also a subtype with a strong association to cigarette
smoking [18]. The influence of carcinogens in the cigarette
smoke results in a high rate of genetic and epigenetic alter-
ations in each tumor [19]. In contrast to adenocarcinomas,
pSQCC usually lack any of the main therapeutic targets like
mutations in EGFR or ALK fusions [20, 21]. In recent years,
new therapeutic options using immunotherapy were devel-
oped, but the benefit for most of the patients with pSQCC
is still limited, and there is a need to explore alternative
approaches [22, 23].
In our study, we aimed at determining the expression
patterns and the prognostic relevance of LAMP2A and
HSC70, the two key players of CMA, in pulmonary SQCC.
2. Materials and Methods
2.1. Cell Lines and Culture Conditions. The human acute
promyelocytic leukemia (APL) cell line, NB4, was obtained
from the German Collection of Microorganisms and Cell
Cultures GmbH (DSMZ, Braunschweig, Germany), and the
SKBR3 breast cancer cells were a kind gift of Professor E.
Garattini (Mario Negri Institute for Pharmacological
Research, Milano, Italy). NB4 cells were maintained in
RPMI-1640 with 10% fetal calf serum (FCS), 50U/mL
penicillin, and 50μg/mL streptomycin, and the SKBR3 cells
were cultured in DMEM/F12, 5% FCS, 50U/mL penicillin,
and 50μg/mL streptomycin. Cells were kept at 5% CO2-
95% air humidified atmosphere at 37°C. The human embry-
onic kidney (HEK) 293 cells expressing SV40-T-antigen
(293T) were a kind gift of Professor B. E. Torbett (Scripps
Research, La Jolla, CA). 293T cells were maintained in
DMEM (Sigma-Aldrich, St. Louis, MO, USA), supplemented
with 5% FBS, 1% penicillin/streptomycin, and 1% Hepes
(Sigma-Aldrich), and kept in 7.5% CO2-95% air humidified
atmosphere at 37°C.
2.2. Cell Lysate Preparation and Western Blotting.Whole cell
extracts were prepared using UREA lysis buffer, and 30-60μg
total protein was loaded on a 12% denaturing polyacrylamide
self-cast gel (Biorad). Blots were incubated with the primary
antibodies in TBS 0.05% Tween-20/5% milk overnight at
4°C (anti-HSC70, Thermofisher MA3-014; anti-LAMP2A,
Abcam 125068), incubated with HRP-coupled secondary
goat anti-rabbit and goat anti-mouse antibody (cell signal-
ing) at 1 : 5–10,000 for 1 h at room temperature.
2.3. Transient Transfection and Lentiviral Vectors. HEK
293T cells were transiently transfected with plasmid pLX307
encoding for HSC70 (HSPA8) using the calcium phosphate
method [24]. pLKO.1-puro lentiviral vectors expressing
shRNAs targeting HSC70 (shHSC70_1: NM_006597.3-
976s1c1, shHSC70_2: NM_006597.3-335s21c1, shHSC70_3:
NM_006597.3-2040s21c1) were purchased from the Sigma-
Aldrich. These vectors contain a puromycin antibiotic
resistance gene for selection of transduced mammalian cells.
Sequences of shRNAs to target LAMP2A were (1) shRNA:
CTGCAACCTGATTGATTA and (2) shRNA: GGCAGG
AGTACTTATTCTAGT. These shRNA sequences were
cloned into a U6-EF1a-IRES-hygro lentiviral vector backbone.
Lentivirus production and transduction were done as
described [25, 26]. Transduced NB4 and SKBR3 cell popula-
tions were selected with 1.5μg/mL puromycin for 4 days,
and knockdown efficiency was assessed by western blot
analysis (Figure 2).
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Figure 1: CMA pathway and validation of LAMP2A immunohistochemical staining. (a) Overview of chaperone-mediated autophagy
(CMA). ① Recognition and binding of HSC70 to the KFERQ-motif of the target protein. ② Translocation of the complex to the
lysosome. ③ Binding of the target protein to LAMP2A at the lysosomal membrane. ④ Formation of a multimeric LAMP2A complex.
⑤ Translocation and degradation of the target protein. (b, c) Specificity of LAMP2A immunohistochemistry. SKBR3 cells were transduced
with lentiviral vectors containing a LAMP2A cDNA (OE) construct, an empty vector control, or shRNAs targeting LAMP2A mRNA
(shLAMP2A_1-2). After selection, cells were subjected to LAMP2A western blot analysis (b) and immunohistochemistry (c).
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2.4. Patient Cohort. In this single center, retrospective study,
we investigated a consecutive cohort of patients with primary
resected pSQCC, diagnosed at the Institute of Pathology,
University of Bern, between 01/2000 and 12/2013. The study
was performed according to the REMARK-guidelines and
was approved by the Cantonal Ethics Commission of the
Canton of Bern (KEK 200/14), which waived the require-
ment for written informed consent. As previously described,
402 patients met the inclusion criteria of the diagnosis
pSQCC according to pathological records [27]. Finally, we
included only tumors with confirmed squamous differentia-
tion according to retrospectively performed immunohisto-
chemical staining for p40 and TTF-1, according to current
guidelines. Additionally, we excluded patients with previous
or concomitant diagnosis of primary SQCC of other organ
systems in order to reliably exclude metastatic lung disease
and patients whose tumors were resected after neoadjuvant
therapy according to reevaluation of clinical files. Tumors
were restaged according to the 8th edition of the UICC
TNM-classification [28, 29]. Tumor grading was reevaluated
in all cases as previously described [30]. In short, grading was
performed according to the cancer grading manual that
evaluates the microscopic extension of keratinization, similar
to the grading of SQCC of other anatomical regions. Grade 1
was assigned to tumors with prominent keratinization
and/or prominent intercellular bridges. Grade 2 was assigned
to tumors with scattered foci of keratinization, less promi-
nent intercellular bridges, smaller tumor cells, or central
comedo-like necrosis. Grade 3 tumors showed only rare or
missing intercellular bridges, no keratin pearls formation,
sheet-like growth, or single cell infiltration. Grade 1 and 2
corresponded to the WHO classification category of kerati-
nizing carcinomas, and Grade 3 depicted nonkeratinizing
carcinomas [31].
Finally, 354 primary resected pSQCC were available for
immunohistochemical analysis. Out of these cases, LAMP2A
and HSC70 could be evaluated in 336 tumors. For the
remaining cases, there was no sufficient tumor material in
the TMA cores, or the immunoreactivity of the tissue was
insufficient due to technical error. Detailed clinicopatho-
logical characteristics are provided in Table 1. Adjuvant
chemotherapy or radiotherapy was administered in 116
patients (35%).
2.5. Next-Generation Tissue Microarray. Immunohistochem-
ical staining was applied on a next generation tissue microar-
ray (ngTMA) constructed as previously described, with
digital annotation of scanned slides and automatic transfer
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Figure 2: Validation of HSC70 immunohistochemical staining. (a, b) HSC70 knockdown in NB4 APL cells. (a) HSC70 knockdown efficiency
of three independent shRNAs (shHSC70_1-3) was determined by western blotting and comparison to scramble shRNA transduced control
cells (SHC002). (b) The most efficient HSC70 knockdown (shHSC70_3) was selected and subjected to immunohistochemistry. (c, d) 293 T
cells were transiently transfected with an empty vector (ctrl) and HSC70 expression plasmid. (c) HSC70 expression was validated by
western blotting. (d) 293 T cells were subjected to HSC70 immunohistochemistry.
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of the punches [32]. Two separate ngTMAs with a total of
four punches per tumor (diameter = 0:6mm) randomly
taken from different tumor regions were used.
2.6. Immunohistochemical Staining and Scoring. Immunohis-
tochemical staining for LAMP2A and HSC70 was done on
4μm sections using an automated immunostainer Leica
Bond RX (Leica Biosystems, Heerbrugg, Switzerland) with
the following conditions (dilution, antigen retrieval):
LAMP2A (Novus Biologicals, Zug, Switzerland, rabbit poly-
clonal, #NB600-1384): 1 : 500, tris buffer, 95°C, and 30min;
and HSC70 (LabForce mbl, Nunningen, Switzerland, rabbit
polyclonal, #PM0045): 1 : 10,000, citrate buffer, 100°C, and
30min. For visualization, the Bond Polymer Refine Detection
kit (Leica Biosystems, Muttenz, Switzerland, DS9800) was
used according to the instructions of the manufacturer.
Scoring of LAMP2A and HSC70 was performed by a
pathologist (TL) on a Zeiss Axioscope microscope at 10x
objective magnification for each TMA core separately. We
assessed the staining intensity in tumor cells ranging from 0
(negative), 1 (weak), 2 (medium) to 3 (strong). The percent-
age of stained tumor cells was determined using the following
increments: 0 ≤ 5%, 1 = 6‐25%, 2 = 26‐50%, 3 = 51‐75%, and
4 = 76‐100%. Finally, the immunoreactivity score (IRS) was
calculated by multiplication of the scores for intensity with
the scores of the percentages of positive tumor cells.
The staining was cytoplasmatic for LAMP2A and HSC70.
Some cases showed both cytoplasmatic and nuclear HSC70
staining. The necrotic areas were strongly positive for both
markers and discarded from the evaluation. The examples
of staining are shown in Figure 3.
The individual IRS was used to assess intratumoral
heterogeneity. For the final determination of the marker
expression level in the tumor, the sum of the IRS over all
cores divided by the number of cores was calculated for each
tumor. The IRS sum score was used for the correlation of the
marker expression with pathological parameters. For survival
analysis, the cohort was first divided into quartiles. The best
prognostic differentiation was observed by stratification of
the results in low expression (lower three quartiles) and high
expression (fourth quartile).
2.7. Statistical Analysis. IBM SPPS Statistics 26 (IBM Corpo-
ration, Armonk, USA) was used for statistical analyses. For
group comparisons, crosstabs, X2 tests, and Fisher’s exact
tests were used. Survival analysis (overall survival and disease
free survival) was calculated from the day of surgery. For
univariate survival analysis, the Kaplan-Meier curves and
log-rank tests were used. For multivariate survival analysis,
the Cox regression analysis was used. p values of <0.05 were
considered as significant for all tests.
3. Results
3.1. Validation of LAMP2A And HSC70 Antibodies for
Immunohistochemistry. First, we validated the specificity of
the antibodies LAMP2A and HSC70 for immunohistochem-
ical staining. We generated a series of LAMP2A and HSC70
knockdown and overexpression cell lines. For this, we used
lentiviral vectors to express LAMP2A cDNA as well as two
independent shRNAs targeting LAMP2A in SKBR3 breast
cancer cells. We confirmed ectopic expression and knock-
down efficiency of LAMP2A by western blot analysis
(Figure 1(b)). We detected a marked overexpression of
LAMP2A compared to parental SKBR3 cells in cells express-
ing the exogenous LAMP2A cDNA. In addition, expression
of both shRNAs targeting LAMP2A resulted in an efficient
depletion of LAMP2A in SKBR3 cells compared to control
transduced cells. Next, FFPE cell pellets were subjected
to LAMP2A immunohistochemical staining. Consistent
with the western blot data, immunohistochemical analysis
revealed increased or depleted LAMP2A expression in
LAMP2A cDNA and shLAMP2A transduced cells, respectively
Table 1: Description of the case collection.
n %
Gender
m 286 85.1
f 50 14.9
Median age (range) 69 (43-85)
pT UICC 2017
pT1a 6 1.8
pT1b 21 6.3
pT1c 45 13.4
pT2a 68 20.2
pT2b 51 15.2
pT3 78 23.2
pT4 67 19.9
pN UICC 2017
pN0 192 57.1
pN1 107 31.9
pN2 37 11.0
Distant metastases
Absent 328 97.6
Present 8 2.4
AJCC/UICC TNM stage 2017
IA1 4 1.2
IA2 17 5.1
IA3 31 9.2
IB 48 14.3
IIA 28 8.3
IIB 88 26.2
IIIA 86 25.6
IIIB 26 7.7
IIIC 0 0.0
IVA 6 1.8
IVB 2 0.6
Grading
Grade 1 7 2.1
Grade 2 170 50.6
Grade 3 159 47.3
Resection status
R0 292 86.9
R1/R2 44 13.1
Total 336 100.0
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(Figure 1(c)). Of note, in agreement with the lysosomal
localization of LAMP2A during CMA, a dot-like staining
pattern was observed for LAMP2A.
Similarly, we generated HSC70 knockdown and overex-
pression cells. We transduced NB4 acute promyelocytic
leukemia (APL) cells with a control and three independent
shRNAs targeting HSC70. Only shHSC70_3 transduced
NB4 cells showed a reduction in HSC70 expression com-
pared to the control transduced cells on a western blot
(Figure 2(a)). This knockdown was confirmed by immuno-
histochemical staining of HSC70 (Figure 2(b)). A transient
overexpression of an HSC70 expression plasmid in 293T
cells resulted in increased protein expression as assessed by
western blotting and immunohistochemistry (Figures 2(c)
and 2(d)). Together, our knockdown and overexpression
experiments in different cell lines underline the specificity
of the anti-LAMP2A and anti-HSC70 antibodies used in
immunohistochemical staining.
3.2. LAMP2A and HSC70 Expression and Intratumoral
Heterogeneity. For determining LAMP2A and HSC70
expression in 336 pSQCC, a total of 1399 TMA cores stained
(a) (b) (c) (d)
(e) (f) (g) (h)
(i) (j) (k) (l)
(m) (n) (o) (p)
Figure 3: Examples of immunohistochemical staining: (a–h) LAMP2A ((a, e) IRS 3x4 = 12; (b, f) IRS 3x2 = 6; (c, g) IRS 1x4 = 4; (d, h) IRS
0x0 = 0); (i–p) HSC70 ((i, m) IRS 3x4 = 12; (j, n) IRS 3x3 = 9; (k, o) IRS 1x4 = 4; (l, p) IRS 0x0 = 0). Objective magnification: (a–d) 13x,
(e–h) 40x, (i–l) 13x, and (m–p) 40x.
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with LAMP2A and 1378 TMA cores stained with HSC70
were available for evaluation. LAMP2A expression was
absent in 109/1399 (8%) of the TMA cores, weak in
286/1399 (20%), medium in 683/1399 (49%), and strong in
321/1399 (23%) cores. The intensity of HSC70 was weak in
146/1378 (11%), medium in 510/1378 (37%), and strong in
708/1378 (51%) of the TMA cores. Only 14/1378 (1%) of
the TMA cores lacked HSC70 expression. IRS multiplying
intensity scores with the extent of tumor staining were calcu-
lated as described in the Material and Methods. For subse-
quent analysis, the IRS of the single cores was used for
assessing intratumoral heterogeneity and the correlation
between the two markers. For the determination of the
expression levels with clinicopathologic characteristics, the
IRS sum scores were calculated for each tumor. Correlations
were performed using either the IRS sum scores or a catego-
rization based on the quartiles of the IRS sum scores.
We identified only 8 cases with additional nuclear expres-
sion of HSC70 (Figures 3(i) and 3(m)), and in this small
group, there was no statistically significant correlation with
other pathological parameters or any valuable prognostic
significance.
There was no significant intratumoral staining heteroge-
neity for LAMP2A and HSC70 when comparing the IRS of
the single cores per tumor of the respective markers among
each other (p values between 0.155 and 0.82). Rather, there
was a highly significant correlation for the IRS within the
four TMA cores per tumor for LAMP2A (r = range 0.751-
0.895; p < 0:001 each) and the IRS of HSC70 (r = range
0.428-0.698; p < 0:001 each).
3.3. Correlation between LAMP2A and HSC70.Due to a close
cooperation of LAMP2A and HSC70 on the molecular level,
the IRS scores of these markers were compared. There was no
significant correlation between the expression of LAMP2A
and HSC70 in the single cores and overall (p values between
0.388 and 0.875; overall: p = 0:68).
3.4. Correlation between LAMP2A and HSC70 Expression
Levels and Pathological Parameters. For the assessment of
associations between LAMP2A and HSC70 expression and
pathological parameters, the IRS scores of each tumor (i.e.,
the sum of all IRS scores across all TMA cores per tumor)
were calculated against the respective factors or were subdi-
vided into quartiles for a categorization into low (lower three
quartiles) to high (highest quartile) expression levels. In
UICC pT1a tumors, the least advanced subgroups of tumors
in the pT category, higher LAMP2A levels and lower HSC70
levels, were observed, but this was overall not statistically
significant when analyzing the entire cohort. For all other
pT categories, IRS levels were within a comparable range.
Similarly, there was no significant association between the
expression of LAMP2A and HSC70 with other pathological
parameters such as pN categories, presence of distant metas-
tases, UICC/AJCC TNM staging and grading, nor with gen-
der or patients’ age. These results were observed using both
calculation methods (IRS sum scores and categorization;
see supplemental Figures S1- S10).
3.5. Correlation with Survival. Survival data was available
for 254 patients. Mean disease free survival (DFS) was
50.1months, and mean overall survival (OS) was 53.9months.
Survival analysis for DFS and OS was calculated using the
expression levels defined by the four quartiles. The best prog-
nostic discrimination was seen for the fourth quartile (then
defined as high expression) versus the lower three quartiles
(defined as low expression). This threshold was then used
for further analysis. IRS cutoffs for differentiating between
low and high staining were 28.0 (summarized from all four
tumor cores) for LAMP2A and IRS 41.8 for HSC70. Low levels
of LAMP2A staining (lower three quartiles) were observed in
255/336 (76%) cases and high levels in 81/336 (24%) cases.
Similarly, we found low levels of HSC70 (lower three quartiles)
in 252/336 (75%) cases and high levels of HSC70 in 84/336
(25%) cases.
High LAMP2A levels were associated with unfavorable
OS (p = 0:012) and DFS (p = 0:049). High HSC70 levels were
also associated with worse outcome, including OS (p = 0:001)
and DFS (p = 0:036) (Figures 4(a)–4(d)).
Applying multivariate analysis, both markers were also
independent adverse prognostic factors for OS and superior
to UICC/AJCC TNM stage (Table 2). For DFS, both markers,
but also UICC/AJCC TNM stage, were independent prog-
nostic factors (Table 3).
The combination of LAMP2A and HSC70 showed an
even more significant prognostic impact: patients with LAM-
P2Ahigh/HSC70high tumors showed the worst prognosis
and patients with LAMP2Alow/HSC70low tumors the
best prognosis (p < 0:001 for OS and p = 0:012 for DFS,
Figures 4(e) and 4(f)). This combination was also an adverse
independent prognostic factor for OS and DFS in multivari-
ate analysis (Tables 4 and 5).
4. Discussion
The role of autophagy and its subtypes, particularly CMA, in
tumorigenesis is complex. As described in previous studies, it
may play a dichotomous role in cancer by suppressing the
initiation of tumor growth but promoting tumor growth
and survival in established cancers [33]. The expression pat-
terns of CMA markers are in the majority still unknown but
could contribute to a better understanding of these complex
and fine-tuned cellular mechanisms.
In our retrospective study, we assessed the immunohisto-
chemical expression patterns of the two CMA key players
LAMP2A and HSC70 and their prognostic value in primary
resected pSQCC. The strength of our study is the large and
histologically homogeneous, well-curated patient cohort
with survival data available for 254 cases and the meticu-
lous validation of specificity of the immunohistochemical
markers used. In order to guarantee the reliability of our
results [34], we generated overexpression and knockdown
cell lines for each marker and validated protein expression
patterns via western blot and immunohistochemistry on
FFPE cell pellets.
We could demonstrate a variable expression of LAMP2A
and HSC70 in pSQCC. There was a wide spectrum of
staining intensity, even though the best prognostic
7Oxidative Medicine and Cellular Longevity
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Figure 4: Continued.
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stratification was observed between strong positive tumors
versus all other staining patterns. Our key finding is that both
markers, LAMP2A and HSC70, are independent adverse
prognostic markers in pSQCC including OS and DFS. The
combination of both of them (LAMP2Ahigh/HSC70high)
showed an even more significant prognostic impact,
although this marker profile was observed in only few cases
(n = 21). This marker profile might correspond to activated
CMA in advanced tumors, which could be required to over-
come the altered metabolism of the tumor cells [13].
Moreover, we found no significant intratumoral hetero-
geneity of LAMP2A and HSC70 staining in the examined
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Figure 4: Kaplan-Meier curves (overall survival and disease free survival) for expression of autophagy-related proteins: (a) OS, LAMP2A;
(b) DFS, LAMP2A; (c) OS, HSC70; (d) DFS, HSC70; (e) OS, combined; (f) DFS, combined.
Table 2: Results of multivariate analysis for OS.
HR
95% CI
p value
Lower Upper
Gender 0.578 0.337 0.990 0.046
Age 2.550 1.785 3.642 <0.001
UICC/AJCC stage 2017 (I, II, III, IV) 1.225 0.974 1.539 0.083
R status 1.705 1.062 2.736 0.027
LAMP2Ahigh 2.059 1.396 3.036 <0.001
HSC70high 1.987 1.368 2.885 <0.001
Table 3: Results of multivariate analysis for DFS.
HR
95% CI
p value
Lower Upper
Gender 0.682 0.423 1.102 0.118
Age 2.059 1.486 2.851 <0.001
UICC/AJCC stage 2017 (I, II, III, IV) 1.233 1.001 1.520 0.049
R status 1.591 1.021 2.480 0.040
LAMP2Ahigh 1.709 1.185 2.467 0.004
HSC70high 1.484 1.046 2.105 0.027
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tumors. There was no significant correlation between these
twomarkers and other pathological parameters. Surprisingly,
there was also no correlation between these two individual
markers, although biologically the two proteins cooperate
in CMA, which underlines the need of further functional
studies in this field. It is important to mention that high
expression levels of HSC70 and LAMP2A are considered
indicative of high CMA levels but are not a proof of high
CMA activity. As CMA is a dynamic process, it cannot be
captured completely using a static method as immunohisto-
chemical staining. High levels of CMA markers could as well
occur in a situation of stalled CMA degradation for instance
if the lysosomal function is impaired.
Similar results have been reported in other tumor types.
LAMP2A is expressed in almost all types of tumors, but the
prognostic value of tumoral expression has not been exten-
sively explored yet. In a recent study on esophageal squa-
mous cell carcinomas, high expression of LAMP2A was
associated with poor prognosis, similar to our findings [35].
High expression levels of HSC70 were observed in many
cancers, e.g., hepatocellular or colon carcinomas [36, 37].
HSC70 was described as a prognostic marker in colorectal
cancer (favorable), liver cancer (unfavorable), and renal can-
cer (favorable) [38]. In our cohort of pSQCC, HSC70 expres-
sion was associated with an unfavorable prognosis. This
discrepancy of the prognostic value of HSC70 might result
from the diversity of HSC70 function in the cell [11].
In lung cancer, the expression of HSP70 was studied
before, another HSP70 family member also known as
HSPA1A or HSP70-1. However, the results are inconsistent,
including a reported better prognosis in patients with
HSP70-positive NSCLC as well as an association with a
Ki-67 proliferation index and nuclear HSP70 expression
[39, 40]. Yet, intense focus has been placed on exploring
the potential of HSP70 inhibitors as chemotherapeutic agents
[10]. For HSC70, however, pharmacological inhibitors were
not available until few years ago. Since this protein is as well
involved in the presentation of antigenic peptides by major
histocompatibility complex class II (MHCII), it was recently
exploited as a target for the treatment of autoimmune disor-
ders [11]. In this context, a phosphopeptide called P140 was
shown to directly interact with HSC70 and to inhibit CMA.
This new drug showed a significant downregulation of the
signaling of autoreactive T cells in vivo in a model of systemic
lupus erythematosus, leading to a remarkable improvement
of the pathophysiologic condition [41]. Thus, HSC70 may
be a possible target to inactivate CMA in future anticancer
therapy, warranting the current detailed expression analyses.
If those aggressive pSQCC with high LAMP2A and HSC70
expression might be candidates for the new CMA-targeting
therapeutics must be further evaluated in functional analyses
and subsequent clinical studies.
Our present work has some limitations warranting subse-
quent validation studies. Importantly, evaluation of the
stainings was performed by only one pathologist. Although
this ensures the application of homogenously calibrated cri-
teria in scoring of all cases, it precludes any statement on
interobserver variability of the scoring method. This will be
addressed in the subsequent studies. Additionally, there is a
possible bias in the sample collection inherent in the retro-
spective design of the study, although all consecutive cases
were included. Finally, evaluation of the stainings was per-
formed on a TMA, which might not represent the entire
tumor when compared to the whole slide. In order to mini-
malize this limitation, a minimum of 4 cores per tumor were
evaluated separately. A comparison of scores between the dif-
ferent cores per tumor failed to show a significant staining
heterogeneity, speaking in favor of the robustness of the
staining pattern throughout the whole tumor [42, 43].
From a biological point of view, the results of our tissue-
based explorative study underline the role of CMA in human
tumorigenesis. From a clinical point of view, the two markers
Table 4: Results of multivariate analysis for OS and LAMP2A/HSC70 marker combination.
HR
95% CI
p value
Lower Upper
Gender 0.581 0.338 0.997 0.049
Age 2.629 1.843 3.751 <0.001
UICC/AJCC stage 2017 (I, II, III, IV) 1.221 0.971 1.536 0.088
R status 1.764 1.100 2.828 0.018
LAMP2Ahigh/HSC70high 1.529 1.287 1.816 <0.001
Table 5: Results of multivariate analysis for DFS and LAMP2A/HSC70 marker combination.
HR
95% CI
p value
Lower Upper
Gender 0.688 0.426 1.110 0.125
Age 2.085 1.508 2.882 <0.001
UICC/AJCC stage 2017 (I, II, III, IV) 1.231 0.998 1.517 0.052
R status 1.612 1.035 2.509 0.035
LAMP2Ahigh/HSC70high 1.342 1.140 1.579 <0.001
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HSC70 and LAMP2A may be exploited as prognostic bio-
markers in pSQCC.
5. Conclusions
In our present study, we demonstrated the variable immuno-
histochemical expression of the key CMA markers LAMP2A
and HSC70 in pSQCC. High expression levels of these
markers were associated with worse prognosis, including
OS and DFS, and could be considered as biomarkers for
potential future CMA inhibiting therapies.
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